Doma Perpetual Capital Management LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Doma Perpetual Capital Management LLC reported 8 stock positions worth $198.0 million. Its top holding was Inmode (INMD) at 19.2% of the portfolio, followed by Banco Bradesco-ADR (BBD, 16.9%) and Napco Security Technologies (NSSC, 14.4%). Compared with Q2 2024, it opened 1 new position, sold out of 2, added to 5 and reduced 1. The biggest buy was a new position in Sirius XM (SIRI) and the biggest sale Davita (DVA, shares −79%).
- Most Recent 13F
- Q2 2026
- Location
- Miami, FL
- CIK
- 0001962221
- Portfolio Value
- $198.0M (Q3 2024)
- SEC Filing
- 0001172661-24-004970 ↗ filed Nov 14, 2024
Holdings Value
Holdings 8 stocks · $198.0M
| INMD Inmode Ltd. | 19.17% | 2,239,323 | $38.0M | Add +11.3% |
| BBD Banco Bradesco-ADR | 16.90% | 12,575,438 | $33.5M | Add +12.2% |
| NSSC Napco Security Technologies | 14.45% | 707,036 | $28.6M | Add +254.4% |
| SIRI Sirius XM Holdings Inc. | 13.84% | 1,158,398 | $27.4M | New |
| PCRX Pacira Biosciences Inc. | 13.29% | 1,747,849 | $26.3M | Add +74.7% |
| HIFS Hingham Institution for SVGS | 11.04% | 89,867 | $21.9M | Add +5.0% |
| DVA Davita Inc. | 8.77% | 105,884 | $17.4M | Reduce -79.0% |
| AFYA Afya Ltd. Class A | 2.54% | 294,909 | $5.0M | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| SIRI Sirius XM Holdings Inc. | New | 13.84% | +13.84 |
| NSSC Napco Security Technologies | Add +254.4% | 14.45% | +9.64 |
| BBD Banco Bradesco-ADR | Add +12.2% | 16.90% | +5.26 |
| HIFS Hingham Institution for SVGS | Add +5.0% | 11.04% | +3.95 |
| INMD Inmode Ltd. | Add +11.3% | 19.17% | +2.16 |
| PCRX Pacira Biosciences Inc. | Add +74.7% | 13.29% | +0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $430.8M | PCRX, NOMD, MBIN, INMD, HIFS |
| Q1 2026 | 11 | $372.4M | PCRX, DVA, MBIN, INMD, AFYA |
| Q4 2025 | 12 | $355.6M | PCRX, INMD, MBIN, NOMD, DVA |
| Q3 2025 | 12 | $297.8M | PCRX, NSSC, DVA, INMD, SIRI |
| Q2 2025 | 10 | $264.0M | BBD, PCRX, DVA, NSSC, INMD |
| Q1 2025 | 10 | $254.4M | PCRX, DVA, INMD, BBD, NSSC |
| Q4 2024 | 8 | $201.0M | INMD, PCRX, SIRI, BBD, NSSC |
| Q3 2024 | 8 | $198.0M | INMD, BBD, NSSC, SIRI, PCRX |
| Q2 2024Amended | 9 | $215.6M | DVA, INMD, PCRX, BBD, LSXMK |
| Q1 2024Amended | 9 | $150.3M | DVA, LSXMK, PCRX, INMD, NSSC |